California hands down millions in fines to Anthem Blue Cross; “street medicine” aims to bring healthcare to the homeless in Atlanta; Johnson & Johnson claims its baby powder is safe.
Anthem Blue Cross in California was fined almost $9.6 million between January 2014 and November 2019 by the state’s Department of Managed Health Care (DMHC), according to California Healthline, for violations that included not covering out-of-network care that should have been covered and wrongly denying claims. That is close to 44% of all penalties for the period. In 2017 alone, Anthem was fined $5 million for letting customer issues drag on for too long, which was eventually negotiated down to $2.8 million and a promise to use $8.4 million for improvements. In total, DMHC has fined licensed health plans $73 million since 2000, its first year.
Mercy Care in Atlanta, Georgia, brings healthcare to the homeless on a daily basis, Kaiser Health News reports, spending close to $900,000 each year since 2013, when its street medicine program began. Outreach personnel include social workers, mental health specialists, and nursing students on 4-week rotations who strive to gain the trust of their often-stigmatized clientele before offering counseling, blood pressure measurements, and flu shots—among the many services they provide. In a non—Medicaid expansion state, Mercy Care hopes to prevent repeated visits to the emergency department, saving money in the process.
Following a voluntary October recall of 1 lot of its Baby Powder—33,000 bottles in the United States—Johnson & Johnson conducted 155 tests via 4 testing methods at 2 third-party labs, contesting claims by the FDA that the powder contains trace amounts of asbestos, according to Reuters. This follows testing also completed in October, with similar results. J&J states that the FDA’s results may be due to sample contamination or lab analyst error, possibly both. J&J has faced increasing scrutiny over the years from lawsuits over baby powder, opioids, and Risperdal, an antipsychotic, among others.
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More